for Sm I, II and IV and 6400 for Sm III, V, and VI.
Since the original observation of Salmon & Daug¬ haday (1957) showing that the action of growth hormone (GH) on rat cartilage is mediated bv peptide components, a number of polvpeptides have been purified sharing the major characteris¬ tics of somatomedins: 1) their serum concentra¬ tions are GH dependent. 2) they stimulate sul¬ phate incorporation into cartilage, 3) thev pro¬ duce insulin-like pleiotvpic actions, and 4) they are a mitogenic stimulus for multiple tissues and cell types (Clemmons & Van Wyk 1981) . The peptides isolated from human plasma by various groups were designated insulin-like growth fac¬ tors I and II (IGF-I and II) (Rinderknecht & Humbel 1976), somatomedin-C (SmC) (Svoboda et al. 1980) , and somatomedin-A (SmA) (Fryklund et al. 1974 ). Elucidation of the primary structure of IGF-I and IGF-II revealed consider¬ able homology in amino acid composition be¬ tween these two peptides and also with proinsulin (Rinderknect & Humbel 1978a,b) . Recently the identity of IGF-I and SmC. has been established by sequence analysis (Klapper et al. 1983) and SmA has been shown to be a less amidated form of IGF-I (Enbergetal. 1984) .
IGF-I/SmC is a basic peptide with an isolelectric point (pi) of 8.2 and a molecular weight of 7649 (Rinderknecht & Humbel 1978a; Svoboda et al. 1980 ). IGF-II is slightly-acidic (pi = 6.5) (Spencer et al. 1983 ) with a molecular weight of 7471 (Rinderknecht & Humbel 1978b) . In plasma, howDownloaded from Bioscientifica.com at 11/04/2018 11:29:26PM via free access ever, these peptides are not present in their low molecular weight form, but thev are complexed with larger carrier proteins (Zapfet al. 1975 ). Besides the two major somatotnedins IGF-I/ SmC and IGF-II somatomdin-like activity-was also observed in the verv basic range (pi >9) (Svoboda et al. 1980; Spencer et al. 1983) and in the acidic range (pi = 4.8) (Cockerill et al. 1980 ), when partially purified preparations from human plasma Cohn fraction IV were subjected to isoelectric focusing.
Recently we have reported on the purification and preliminary characterization of four peptides of the somatomedin family from human plasma (Blum et al. 1984) . In order to obtain larger quantities of these peptides, an improved pro¬ cedure for the isolation of somatomedins from human plasma Cohn fraction IV was developed utilizing a competitive protein binding assav to monitor purification. Six Bradford ( 1976) using the Bio-Rad assay kit. Somatomedin in vitro bioassay. Bioactivity of the purified peptides Sm I-VI was measured in vitro by using the porcine costal cartilage assay described by Van den Brande 8c Du Cajú (1974) . In order to prevent irrever¬ sible adsorption of the peptides to the test tubes, the addition of 0.19? fatty acid free bovine serum albumin to the incubation medium was mandatory. A serum pool from normal adult donors was used as standard.
One unit of somatomedin is defined as the activity of isolation a competitive protein binding assay described by Schalch et al. (1978) was adopted. The tracer was prepared from a highly purified IGF-I-like peptide corresponding to Sm III previously isolated from hu¬ man plasma (Blum et al. 1984) with rat liver cell membranes as described by Koch 8c Weber (1981) (Fig. 2) SDS-PAGE of the purified peptides after re¬ duction with 2-mercaptoethanol yielded single bands (Fig. 5) . Molecular weights were estimated from a run with smaller sample loads giving narrower bands (not shown). They were deter¬ mined as 6800 for Sm I, II, and IV and 6400 for Sm III, V. and VI.
Determination of molecular weights by gel chromatography with Sephadex G-50 Superfine at neutral pH confirmed the relatively larger size of Sm I, II, and IV. The estimates obtained by this method, however, were higher than by SDS-PAGE. They ranged from 9800 (Sm I) to 7100 (Sm VI).
Activities ofpurified somatomedins in various assays
The in vitro bioactivities of all six purified pep¬ tides in the porcine costal cartilage assay were identical (Fig. 6) . Incorporation of sulphate increased almost linerarly between 1 and 10 000 ng peptide per ml. The dose-response curve obtained with standard serum, however, was not parallel to the curves obtained with the purified peptides. Its slope was about two-fold steeper. Identical poten¬ cies of Sm I -VI were also observed in the CPBA (Fig. 7a) .
The radioimmunoassays, however, revealed sig¬ nificant differences between the various peptides.
While the dose-response curves of Sm I, II and III were virtually superimposable in the SmC-RIA, the displacement curve of Sm IV was shifted to higher dose-values by two orders of magnitude (Fig. 7b) . Sm V and VI were even less potent and their dose-response curves were not parallel to the curves obtained with Sm I -IV. Only the slightly acidic somatomedins (Sm IV-VI) were active in the IGF-II-C-peptide assay (Fig. 7c) . The relative potencies of Sm IV and Sm VI were 17% and 57% respectively as compared to Sm V which was the most potent peptide. An opposite result was obtained with the IGF-I-C-peptide assay (Fig. 7d) . (from left to right) after SDS electrophoresis.
The slightly acidic peptides were inactive, while only the basic somatomedins were able to displace the tracer.
Comparable findings were obtained with the radioreceptor assays. Utilizing human placental cell membranes and Sm III as tracer, the basic peptides were significantly more active than the acidic ones (Fig. 8a) . In contrast to the SmC-RIA, however, the potencies of Sm I and II were only about 507c of Sm III and Sm IV was 3-fold less potent than Sm V. In the Sm-V-RRA, utilizing rat liver cell membranes and Sm V as tracer, Sm IV -VI were highly active yielding similar dis¬ placement curves. The basic peptides (Sm I -III) were considerably-less potent in this assay system (Fig. 8b) . (Rinderknecht & Humbel 1978a,b 
